ISSN: 2329-6607
Cardiovascular Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
Editorial
Open Access
 

The Glycoform Modifications of sRAGE Matter

Hyun-Jin Tae Edward G Lakatta Li Lin*
Laboratory of Cardiovascular Sciences, National Institute on Aging, NIH, Baltimore, MD, USA
Corresponding Author : Li Lin
Laboratory of Cardiovascular Sciences
National Institute on Aging
NIH, Baltimore, MD21224, USA
E-mail: linli@mail.nih.gov
Received July 26, 2013; Accepted July 26, 2013; Published July 30, 2013
Citation: Tae HJ, Lakatta EG, Lin L (2013) The Glycoform Modifications of sRAGE Matter. Cardiol Pharmacol 2:e114. doi:10.4172/2329-6607.1000e114
Copyright: © 2013 Tae HJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
Visit for more related articles at Cardiovascular Pharmacology: Open Access
 
The signaling of Receptors for Advanced Glycation End Products (RAGE) results in inflammation and tissue remodeling, and has been implicated in several human diseases, including cardiovascular disease [1-3]. Soluble RAGE (sRAGE) encompassing the entire ectoportion of RAGE, but lacking the membrane anchor and cytosolic signaling domain, functions as a decoy that counteracts RAGE-mediated inflammatory signaling by competing for RAGE ligands and dampening the subsequent inflammation and tissue remodeling [4]. RAGE/sRAGE is known to be modified by N-linked glycosylation at two locations of the ligand binding V ectodomain [5], and such modification has been shown to be important for RAGE bioactivity [6,7]. Recombinant sRAGE has been generated and tested in several disease models in mice [8-10] or rats [11], and the results have shown a promise for future clinical applications. However, in these studies, recombinant sRAGE was produced in the fall armyworm (Spodoptera frugiperda) cell line sf9 via a baculovirus vector [8-11], rather than in mammalian source, making immunogenicity as well as bioactivity an issue.
Although glycoproteins expressed in insect and mammalian cells are both glycosylated, their glycoforms are different. Insect cells predominantly produce paucimannose N-glycans, whereas mammalian cells can produce highly diverse N-glycoforms including paucimannose, hybrid, and most often, complex type of glycans [12]. These different forms of post-translational modification may impact a therapeutic glycoprotein in the following aspects.
First, glycoforms act as antigens in vivo. Insect cell-originated N-glycoforms are immunogenic in mammalian system. Currently, major regulatory authorities (FDA, EMEA) require that therapeutic glycoproteins to be produced in mammalian cell lines such as Chinese Hamster Ovary (CHO) cells and Human Embryonic Kidney cells (HEK293), or in mammalian sources via transgenic animals to avoid adverse side-effects and biosafety concerns [13].
Second, glycoforms contribute to bioactivities or in vivo duration of a glycoprotein, directly affecting its therapeutic efficacy [14]. A typical example is recombinant human Erythropoietin (EPO), a therapeutic glycoprotein used for the treatment of anemia-associated diseases. Proper glycosylation significantly enhances EPO bioactivity and duration of action in vivo [15]. Other examples include recombinant TNK-tissue plasminogen activator [16], and Soluble Intercellular Adhesion Molecule-1 (sICAM-1) [17].
Although direct evidence regarding N-glycoform modifications and sRAGE in vivo efficacy is still lacking, results from several studies have shown that N-glycoform modifications may contribute to RAGE signaling capacity and sRAGE activity in vitro. Genetic studies have shown that patients with a G82S polymorphism in AGER (the gene encoding RAGE) are prone to the development of diabetes [6]. Subsequent biochemical studies demonstrated that this polymorphism enhances RAGE N-glycosylation at residue N81, and affects RAGE signal transduction [7]. Since RAGE and sRAGE share the ectodomains, it can be inferred that sRAGE with proper N-glycoform modifications may interact with RAGE ligands more effectively, and thus has higher blocking capacity. Indeed, earlier studies have also shown that sRAGE purified form animal lung tissues is more effective than that of sf9 cell-originated sRAGE to block RAGE ligand-induced vascular smooth cell migration in vitro. Recently, Srikrishna and colleagues showed that a small portion of sRAGE from lung tissue, modified by carboxylated N-glycoforms, has higher bioactivity to block NF-κB in vitro than that of sRAGE produced in sf9 cells [18]. These studies support the general concept that a proper N-glycoform modification is critical for a glycoprotein’s bioactivity and therapeutic efficacy also applies to sRAGE.
Furthermore, the reported dosage of sf9 cell-originated sRAGE is relatively high, i.e. 100 μg/mouse/day for mice [8-10], or 0.5 mg/kg body weight for rats [11]. In addition, either mouse or rat models used for blocking studies required daily sRAGE administration to achieve desired therapeutic outcomes. These suggest that the bioactivity of sf9 cell-originated recombinant sRAGE is relatively low. Significantly, a recent report showing that a similar dose of sf9 cell-originated sRAGE (5 μg/g body weight, assuming an average lab mouse weighs 20 g) elicits monocyte inflammatory reactions in mice [19]. This observation further begs the question of whether it is apt to use sf9 cell-originated, rather than the mammalian cell-originated sRAGE with proper N-glycoform modifications in animal studies.
In our opinion, the specific N-glycoform modification of sRAGE matters. Systematic studies of the bioactivity and assessment of the in vivo efficacy of mammalian cell-originated recombinant sRAGE in animal models will test this concept. Information gleaned from these studies will render a more adequate assessment of sRAGE’s therapeutic potential, including possible reduction of administrated dosage and administration frequency, owing to higher bioactivity and/or in vivo efficacy that are resulted from using a proper N-glycoform modified form. These studies will also provide a basis for further development of sRAGE as a candidate pharmacological glycoprotein for future clinical applications.
Acknowledgements
Our work is supported entirely by the Intramural Research Program of NIH, National Institute on Aging.
References



















References




















Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Ablation Surgery
Disc Acute Coronary Syndrome
Disc Angina Pectoris
Disc Angiogenesis
Disc Aortic Dissection
Disc Atrial Fibrillation
Disc Bypass Surgery
Disc Cardiac Arrest
Disc Cardiac Cachexia
Disc Cardiac Catheterization
Disc Cardiac Dysrhythmias
Disc Cardiac Electrophysiology
Disc Cardiac Surgery
Disc Cardiac biomarkers
Disc Cardiomyopathy
Disc Cardiopulmonary Resuscitation
Disc Cardiovascular Diseases
Disc Cardiovascular Drugs
Disc Cardiovascular Drugs Market Analysis
Disc Cardiovascular Medicine
Disc Cardiovascular Pharmacotherapy
Disc Cardiovascular Physiology
Disc Cardiovascular Safety Pharmacology
Disc Cardiovascular Toxicology
Disc Cineangiography
Disc Congenital Heart Disease
Disc Congestive Heart Failure
Disc Coronary Artery Disease
Disc Coronary Heart Disease
Disc Cyanotic Heart Disease
Disc Drug Side Effect
Disc Echocardiography
Disc Endocarditis
Disc Heart Attack
Disc Heart Diseases
Disc Heart Failure
Disc Heart Transplants
Disc Invasive Cardiology
Disc Molecular Pharmacology
Disc Myocardial Infarction
Disc Neuropharmacology
Disc Open Heart Surgery
Disc Percutaneous Coronary Intervention
Disc Pharmacoepidemiology
Disc Pharmacogenomics
Disc Pharmacokinetics
Disc Pharmacotherapeutics
Disc Pulmonary Embolism
Disc Rheumatic Heart Disease
Disc Sudden Cardiac arrest
Disc Systems Pharmacology
Disc Theoretical Pharmacology
 
Recommended Journals
Disc Cardiovascular Diseases Journal
Disc Experimental Cardiology Journal
Disc Clinical Pharmacology Journal
  View More»
 
Recommended Conferences
Disc Cardio Vascular Medicine Conference
August 01-02, 2016 Manchester, UK
Disc Cardiovascular Nursing Conference
August 08-10, 2016 Las Vegas,USA
Disc 13th Cardiology Congress
Oct 24-26, 2016, Valencia, Spain
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11203
  [From(publication date):
November-2013 - Jun 26, 2016]
  Breakdown by view type
  HTML page views : 7475
  PDF downloads :3728
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version